Abstract LB267: Evaluating the therapeutic potential of novel TrkA agonists in targeting glioblastoma stem cells (GSCs)

胶质母细胞瘤 干细胞 癌症研究 药理学 医学 癌症干细胞 肿瘤科 癌症 生物 内科学 遗传学
作者
Tom Jackson,David E. Johnson,Hawa Jagana,Leyre Merino-Galán,Siobhan S. Pattwell,Thomas Schlichthaerle,Natasha I. Edman,David Baker
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_2): LB267-LB267
标识
DOI:10.1158/1538-7445.am2025-lb267
摘要

Abstract Background: Glioblastoma multiforme (GBM) is the most frequent malignant central nervous system tumor in adults, with an average survival rate of approximately 15 months. In children, high grade gliomas, such as diffuse intrinsic pontine glioma (DIPG), are equally aggressive and present unique challenges due to developmental differences in the brain and the limited treatment options available. One model for studying high grade gliomas lies within a population of stem-like cells, known as glioblastoma stem cells (GSCs). GSCs exhibit self-renewal capabilities, resistance to conventional therapies, and the ability to drive tumor recurrence and progression. Understanding and targeting GSCs is necessary for developing therapies that can improve treatment outcomes in both adult and pediatric patients suffering from high grade gliomas. A family of neurotrophin receptors known as the tropomyosin receptor kinases (TRKs), including TrkA, TrkB, and TrkC, encoded by the NTRK1, NTRK2, and NTRK3 genes respectively, are critical for normal neuronal development and survival. In brain tumors, the canonical signaling of these receptors is often corrupted through gene fusions or overexpression, leading to abnormal activation of signaling pathways that promote tumor cell survival, self-renewal, and resistance to treatment. Here, we investigate the use of novel agonists 231 and 237, developed by our team, to specifically target TrkA, in effort to better understand its role in GSC biology, with the goal of finding ways to inhibit tumor growth and improve therapeutic outcomes in high grade glioma models. GSC lines 448T and 559T were cultured under standard conditions to investigate the effects of novel TrkA agonists (231 and 237) on proliferation, differentiation, and TrkA/TrkB expression. Synergy with targeted therapies, including Abemaciclib (a CDK4/6 inhibitor) and Altiratinib (a multi-kinase inhibitor targeting MET, VEGFR2, and Trk pathways), was also evaluated. For proliferation and Western blot analysis, cells were treated with PBS (control), 231, or 237 for 72 hours, followed by cell counting and lysate preparation. Differentiation was assessed using neurite outgrowth assays with Incucyte Live-Cell Imaging and Neurotrack software, measuring neurite length, branch points, and neurite-bearing cells. Western blot analysis demonstrated a reduction in TrkA expression in 559T glioblastoma stem cell lines treated with novel TrkA-specific agonists 231 and 237 compared to the PBS control. This decrease suggests potential downregulation of TrkA or feedback inhibition in response to agonist treatment. Ongoing studies aim to further elucidate the mechanisms underlying TrkA modulation and its role in maintaining GSCs in vitro. Additionally, investigations are exploring the potential synergistic effects of TrkA-specific agonists with targeted therapies to enhance GSC susceptibility to treatment. Citation Format: Taylor Simone Jackson, David E. Johnson, Hawa L. Jagana, Leyre Merino-Galan, Siobhan S. Pattwell, Thomas Schlichthaerle, Natasha Edman, David Baker. Evaluating the therapeutic potential of novel TrkA agonists in targeting glioblastoma stem cells (GSCs) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB267.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
1秒前
orixero的应助被han采纳,获得20
1秒前
2秒前
Lucas的应助被tiezhu采纳,获得10
2秒前
kwokai完成签到,获得积分10
2秒前
饼子完成签到 ,获得积分10
2秒前
3秒前
3秒前
3秒前
小蘑菇的应助被shiyi11采纳,获得10
4秒前
汤一德完成签到,获得积分10
4秒前
4秒前
做生活的嚼嚼者完成签到,获得积分10
5秒前
5秒前
啦啦啦发布了新的文献求助10
5秒前
香蕉觅云的应助被阔叶采纳,获得10
6秒前
然12138完成签到,获得积分10
7秒前
赫江涛发布了新的文献求助10
7秒前
8秒前
可爱的函函的应助被罗斯味SF采纳,获得10
8秒前
8秒前
闪闪婴发布了新的文献求助10
8秒前
闪闪婴发布了新的文献求助10
8秒前
闪闪婴发布了新的文献求助10
8秒前
闪闪婴发布了新的文献求助10
8秒前
闪闪婴发布了新的文献求助10
8秒前
XIXILI完成签到 ,获得积分10
9秒前
9秒前
wengarak发布了新的文献求助10
10秒前
11秒前
个性的夜白完成签到,获得积分10
11秒前
爱沉淀的太阳花完成签到,获得积分10
12秒前
Organic123发布了新的文献求助10
12秒前
12秒前
12秒前
Wookie发布了新的文献求助10
13秒前
14秒前
CHINA_CNN完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192078
求助须知:如何正确求助?哪些是违规求助? 9578670
关于积分的说明 21861341
捐赠科研通 7791469
什么是DOI,文献DOI怎么找? 3436771
关于科研通互助平台的介绍 2560538
邀请新用户注册赠送积分活动 2483557